<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Plant Foods Hum Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Plant Foods Hum Nutr</journal-id><journal-title-group><journal-title>Plant Foods for Human Nutrition (Dordrecht, Netherlands)</journal-title></journal-title-group><issn pub-type="ppub">0921-9668</issn><issn pub-type="epub">1573-9104</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998708</article-id><article-id pub-id-type="pmc">PMC11861005</article-id>
<article-id pub-id-type="publisher-id">1309</article-id><article-id pub-id-type="doi">10.1007/s11130-025-01309-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effects of Sacha Inchi (<italic>Plukenetia volubilis</italic> L.) Oil Supplementation on Hyperglycaemia, Hypertension and Hyperlipidaemia (3Hs) Patients: A Preliminary Human Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mhd Rodzi</surname><given-names>Nur Anis Raihana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohd Sopian</surname><given-names>Mastura</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Lai Kuan</given-names></name><address><email>l.k.lee@usm.my</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02rgb2k63</institution-id><institution-id institution-id-type="GRID">grid.11875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 3534</institution-id><institution>Present Address: Food Technology Program, School of Industrial Technology, </institution><institution>Universiti Sains Malaysia, </institution></institution-wrap>Gelugor, Pulau Pinang 11800 Malaysia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02rgb2k63</institution-id><institution-id institution-id-type="GRID">grid.11875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 3534</institution-id><institution>Clinical Medicine Department, </institution><institution>Universiti Sains Malaysia Bertam Medical Centre, </institution></institution-wrap>Kepala Batas, Pulau Pinang 13200 Malaysia </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>80</volume><issue>1</issue><elocation-id>80</elocation-id><history><date date-type="accepted"><day>3</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Sacha Inchi oil (SIO), derived from seeds of <italic>Plukenetia volubilis L.</italic>, is a novel plant source of unsaturated fatty acids, highly regarded for its health benefits. The rich fractions of polyunsaturated fatty acids have shown potential in improving or reducing the impact of hyperglycaemia, hypertension and hyperlipidaemia (3Hs) for both in vivo and preliminary human studies. This study aimed to investigate the effects of SIO supplementation on glycaemic, lipid and blood pressures outcomes of patients with 3Hs. A randomised, double-blind, placebo-controlled human clinical trial was conducted to investigate the effects of SIO supplementation in fifty-four (<italic>n</italic> = 54) 3Hs patients. Assessments of glycaemic control, blood pressure and lipid profiles were conducted and compared at baseline and week-12 after 3Hs patients were randomised into SIO group (<italic>n</italic>&#x02009;=&#x02009;27) (received 1000&#x000a0;mg of SIO soft gel per day) or the placebo group (<italic>n</italic>&#x02009;=&#x02009;27) (received 1000&#x000a0;mg of corn oil), with prescribed medications. The compliancy and tolerability of supplementation were assessed concurrently. The SIO group demonstrated lower systolic (-8.6 mmHg, <italic>p</italic>&#x02009;=&#x02009;0.004) and diastolic blood pressure (BP) (-7.0 mmHg, <italic>p</italic>&#x02009;=&#x02009;0.004), total cholesterol (TC) (-0.6 mmol/L, <italic>p</italic>&#x02009;=&#x02009;0.024), low density lipoprotein-cholesterol (LDL-C) (-0.3 mmol/L, <italic>p</italic>&#x02009;=&#x02009;0.036) and high density lipoprotein-cholesterol (HDL-C) (<italic>p</italic>&#x02009;=&#x02009;0.048) but no effect on glycaemic markers. No clinical adverse events were reported, and the side effects of SIO supplementation were self-limiting and minimal. SIO supplementation showed the potential to alleviate BPs, reduced both TC and LDL-C, and improved HDL-C levels. SIO may offer a simple, novel complementary medicine for the management of 3Hs.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11130-025-01309-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Complementary medicine</kwd><kwd>Sacha inchi</kwd><kwd>Polyunsaturated fatty acids</kwd><kwd>Hyperglycaemia</kwd><kwd>Hyperlipidaemia</kwd><kwd>Hypertension</kwd></kwd-group><funding-group><award-group><funding-source><institution>Orient Biotech Sdn Bhd</institution></funding-source><award-id>304/PTEKIND/6501176</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Hyperglycaemia, characterised by elevated blood glucose due to insulin resistance (IR) and &#x003b2;-cell dysfunction, is a key feature of type 2 diabetes mellitus (T2DM) [<xref ref-type="bibr" rid="CR1">1</xref>]. Hypertension or elevated blood pressure (BP) is another component of metabolic syndrome, both of which can lead to peripheral vascular disease, kidney damage, and visual impairment [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Hyperlipidaemia, defined by elevated fasting cholesterol, is often associated with increased triglycerides (TG) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. These conditions may arise from various comorbidities or lifestyle factors and their presence independently increases cardiovascular risk [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par3"><italic>Sacha</italic> Inchi oil (SIO) is gaining popularity owing to its high content of omega-3 (&#x02126;-3) fatty acids, such as alpha linolenic acid (ALA) [<xref ref-type="bibr" rid="CR7">7</xref>]. ALA activates the receptor responsible for insulin sensitisation and the enhancement of glucose metabolism (PPARy) [<xref ref-type="bibr" rid="CR8">8</xref>]. Clinical trials have suggested significant reductions in BP following plant-based oil [<xref ref-type="bibr" rid="CR9">9</xref>]. Omega-3 fatty acids exert lowering effects in hyperlipidaemic patients by decreasing hepatic lipogenesis, increasing &#x003b2;-oxidation, inhibiting key enzymes involved in hepatic TG synthesis, and increasing the expression of lipoprotein lipase, leading to increased TG removal from circulating very low density lipoprotein (VLDL) and chylomicron particles [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par4">A pioneer, double-blind, randomised, crossover trial found that 15&#x000a0;ml SIO supplementation into high-fat breakfast among the metabolically unhealthy individuals reduced blood glucose levels and increased Sirtuin (SIRT-1) expression, a protein that enhances insulin secretion and activates insulin pathways [<xref ref-type="bibr" rid="CR12">12</xref>]. Contradictorily, a 4 months trial (10 or 15&#x000a0;ml SIO supplementation given to healthy adults) did not exhibit any significant change in regular and fasting blood glucose (FBG) levels [<xref ref-type="bibr" rid="CR13">13</xref>]. Another trial conducted among the hypercholesterolaemic patients reported significant reductions in lipid profiles after 4 months of SIO supplementation [<xref ref-type="bibr" rid="CR14">14</xref>]. In animal study, daily ingestion of 400&#x000a0;mg/kg Sacha Inchi diet was capable to reduce BP and improved oxidative damage in rats [<xref ref-type="bibr" rid="CR15">15</xref>]. In an earlier study, 0.5&#x000a0;ml/kgBW of SIO in Holtzman rats improved liver function, lowered cholesterol level and TG, increased HDL-C, and elevated insulin levels [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par5">To the best of our knowledge, no research has examined the effects of SIO supplementation as a complimentary regimen for 3Hs patients. This study aimed to assess the effects of SIO supplementation on primary 3H indicators, including FBG, glycated haemoglobin (HbA1c), fasting serum insulin, insulin resistance (HOMA-IR), systolic and diastolic BP, and lipid profiles. The safety, tolerability, and adherence to the supplementation were also evaluated.</p></sec><sec id="Sec2"><title>Materials and Methods</title><p id="Par6">The Materials and Methods section is presented as supplementary material.</p></sec><sec id="Sec3"><title>Results and Discussions</title><sec id="Sec4"><title>Subjects</title><p id="Par7">This was the first randomised human clinical trial in the Southeast Asia to evaluate the effects of SIO supplementation among patients with 3Hs. Fifty-four 3Hs patients were randomly categorised into the SIO or placebo group (<italic>n</italic>&#x02009;=&#x02009;27 <italic>per</italic> group). At baseline, we observed no significant difference in any of the socio-demographic characteristics, nutritional status assessments, and the plasma fatty acid composition. The SIO group, however, performed more frequent physical activity (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), while a greater proportion of patients in the placebo group were smokers (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Table <xref rid="MOESM2" ref-type="media">S5</xref>).</p></sec><sec id="Sec5"><title>Effects of SIO Versus Placebo Supplementation on Glycaemic Markers</title><p id="Par8">The baseline and post intervention glycaemic marker levels are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. No significant changes in FBG, HbA1c, FSI or HOMA-IR were detected either in the SIO or placebo group. Hence, our study suggested that SIO supplementation did not affect glycaemic marker levels, in line with Foster et al. [<xref ref-type="bibr" rid="CR17">17</xref>]. However, Alay&#x000f3;n et al. [<xref ref-type="bibr" rid="CR12">12</xref>] showed an attenuation effect on the elevation of blood glucose and a marked increase in the expression of SIRT-1 in the SIO group. SIRT1 is a vital protein in the human body that stimulates glucose-dependent insulin secretion [<xref ref-type="bibr" rid="CR12">12</xref>]. According to a recent meta-analysis, plant-derived omega-3 PUFA supplementation ameliorates insulin resistance [<xref ref-type="bibr" rid="CR18">18</xref>]. It is believed that omega-3 PUFAs reduce FBG levels by enhancing the sensitivity of insulin signals induced by G-coupling receptors of glucagon-like peptide 1 (GLP-1) and regulating the signalling pathways involved in insulin production [<xref ref-type="bibr" rid="CR19">19</xref>]. The discrepant findings suggest the need for a larger sample size for human trials, and future studies are needed to unravel the complex interrelationship between SIO consumption and glycaemic control.</p><p id="Par9">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Effects of SIO versus placebo on glycaemic markers, blood pressure and lipid profile</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left"/><th align="left">Baseline</th><th align="left">12-week</th><th align="left">
<italic>p</italic>
<sup>1</sup>
</th><th align="left">
<italic>p</italic>
<sup>2</sup>
</th><th align="left">F</th><th align="left">Power</th><th align="left">&#x003b7;p<sup>2</sup></th></tr></thead><tbody><tr><td align="left">FBG (mmol/L)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">8.6&#x02009;&#x000b1;&#x02009;3.1</td><td char="&#x000b1;" align="char">8.7&#x02009;&#x000b1;&#x02009;2.8</td><td char="." align="char">0.781</td><td char="." align="char">0.416</td><td char="." align="char">0.679</td><td char="." align="char">0.126</td><td char="." align="char">0.020</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">7.3&#x02009;&#x000b1;&#x02009;1.8</td><td char="&#x000b1;" align="char">7.8&#x02009;&#x000b1;&#x02009;2.3</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HbA1c (%)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">7.6&#x02009;&#x000b1;&#x02009;2.1</td><td char="&#x000b1;" align="char">7.5&#x02009;&#x000b1;&#x02009;1.5</td><td char="." align="char">0.869</td><td char="." align="char">0.151</td><td char="." align="char">2.159</td><td char="." align="char">0.298</td><td char="." align="char">0.058</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">7.1&#x02009;&#x000b1;&#x02009;1.2</td><td char="&#x000b1;" align="char">7.3&#x02009;&#x000b1;&#x02009;1.2</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">FSI (microIU/mL)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">15.8&#x02009;&#x000b1;&#x02009;0.6</td><td char="&#x000b1;" align="char">15.8&#x02009;&#x000b1;&#x02009;0.5</td><td char="." align="char">0.388</td><td char="." align="char">0.389</td><td char="." align="char">0.762</td><td char="." align="char">0.136</td><td char="." align="char">0.021</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">15.8&#x02009;&#x000b1;&#x02009;0.8</td><td char="&#x000b1;" align="char">15.7&#x02009;&#x000b1;&#x02009;0.7</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HOMA-IR</td><td align="left">SIO</td><td char="&#x000b1;" align="char">6.0&#x02009;&#x000b1;&#x02009;2.1</td><td char="&#x000b1;" align="char">6.1&#x02009;&#x000b1;&#x02009;2.0</td><td char="." align="char">0.791</td><td char="." align="char">0.347</td><td char="." align="char">0.908</td><td char="." align="char">0.153</td><td char="." align="char">0.025</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">5.1&#x02009;&#x000b1;&#x02009;1.2</td><td char="&#x000b1;" align="char">5.4&#x02009;&#x000b1;&#x02009;1.7</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">SBP (mmHg)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">143.9&#x02009;&#x000b1;&#x02009;2.6</td><td char="&#x000b1;" align="char">135.3&#x02009;&#x000b1;&#x02009;2.5</td><td char="." align="char">0.003**</td><td char="." align="char">0.004**</td><td char="." align="char">8.962</td><td char="." align="char">0.835</td><td char="." align="char">0.152</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">143.9&#x02009;&#x000b1;&#x02009;2.5</td><td char="&#x000b1;" align="char">144.6&#x02009;&#x000b1;&#x02009;2.5</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">DBP (mmHg)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">83.9&#x02009;&#x000b1;&#x02009;1.4</td><td char="&#x000b1;" align="char">76.9&#x02009;&#x000b1;&#x02009;1.5</td><td char="." align="char">&#x0003c;&#x02009;0.0001**</td><td char="." align="char">0.004**</td><td char="." align="char">9.271</td><td char="." align="char">0.848</td><td char="." align="char">0.156</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">82.6&#x02009;&#x000b1;&#x02009;1.4</td><td char="&#x000b1;" align="char">81.9&#x02009;&#x000b1;&#x02009;1.5</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">TC (mmol/L)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">5.1&#x02009;&#x000b1;&#x02009;0.6</td><td char="&#x000b1;" align="char">4.5&#x02009;&#x000b1;&#x02009;0.6</td><td char="." align="char">&#x0003c;&#x02009;0.0001***</td><td char="." align="char">0.024*</td><td char="." align="char">5.607</td><td char="." align="char">0.633</td><td char="." align="char">0.633</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">4.6&#x02009;&#x000b1;&#x02009;0.8</td><td char="&#x000b1;" align="char">4.6&#x02009;&#x000b1;&#x02009;1.3</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">LDL-C (mmol/L)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">2.5&#x02009;&#x000b1;&#x02009;0.9</td><td char="&#x000b1;" align="char">2.2&#x02009;&#x000b1;&#x02009;0.7</td><td char="." align="char">0.008**</td><td char="." align="char">0.036*</td><td char="." align="char">4.771</td><td char="." align="char">0.565</td><td char="." align="char">0.123</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">2.5&#x02009;&#x000b1;&#x02009;0.8</td><td char="&#x000b1;" align="char">2.7&#x02009;&#x000b1;&#x02009;1.2</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HDL-C (mmol/L)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">1.2&#x02009;&#x000b1;&#x02009;0.2</td><td char="&#x000b1;" align="char">1.2&#x02009;&#x000b1;&#x02009;0.2</td><td char="." align="char">0.975</td><td char="." align="char">0.048*</td><td char="." align="char">4.114</td><td char="." align="char">0.512</td><td char="." align="char">0.076</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">1.2&#x02009;&#x000b1;&#x02009;0.1</td><td char="&#x000b1;" align="char">1.1&#x02009;&#x000b1;&#x02009;0.1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">TG (mmol/L)</td><td align="left">SIO</td><td char="&#x000b1;" align="char">1.7&#x02009;&#x000b1;&#x02009;0.7</td><td char="&#x000b1;" align="char">1.7&#x02009;&#x000b1;&#x02009;0.6</td><td char="." align="char">0.656</td><td char="." align="char">0.876</td><td char="." align="char">0.025</td><td char="." align="char">0.053</td><td char="." align="char">0.000</td></tr><tr><td align="left"/><td align="left">Placebo</td><td char="&#x000b1;" align="char">1.6&#x02009;&#x000b1;&#x02009;0.5</td><td char="&#x000b1;" align="char">1.7&#x02009;&#x000b1;&#x02009;0.5</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD)</p><p>*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p><p><italic>p</italic><sup><italic>1</italic></sup>&#x02009;=&#x02009;<italic>p</italic> values generated using Independent Student&#x02019;s t-test; <italic>p</italic><sup><italic>2</italic></sup>&#x02009;<italic>=&#x02009;p</italic>-values are reported based on repeated measures ANCOVA after adjustment for age, physical activity, smoking status and prescribed medication</p><p>FBG&#x02009;=&#x02009;fasting blood glucose; HbA1c&#x02009;=&#x02009;glycated haemoglobin A1c; FSI&#x02009;=&#x02009;fasting serum insulin; HOMA-IR&#x02009;=&#x02009;homeostatic model assessment of insulin resistance, SBP&#x02009;=&#x02009;systolic blood pressure; DBP&#x02009;=&#x02009;diastolic blood pressure, TC&#x02009;=&#x02009;total cholesterol; LDL-C&#x02009;=&#x02009;low-density lipoprotein cholesterol; HDL-C&#x02009;=&#x02009;high-density lipoprotein cholesterol; TG&#x02009;=&#x02009;triglyceride</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec6"><title>Effects of SIO Versus Placebo Supplementation on Systolic and Diastolic BPs</title><p id="Par10">Compared with the placebo group, 3Hs patients who received SIO had significantly lower systolic (-7.8&#x02009;&#x000b1;&#x02009;0.6 vs. -0.04&#x02009;&#x000b1;&#x02009;0.3 mmHg; <italic>p</italic>&#x02009;=&#x02009;0.004) and diastolic BP (-7.1&#x02009;&#x000b1;&#x02009;1.1 vs. -0.6&#x02009;&#x000b1;&#x02009;1.1 mmHg; <italic>p</italic>&#x02009;=&#x02009;0.004) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Previous study reported that 10 or 15 mL of SIO emulsion reduced arterial BPs [<xref ref-type="bibr" rid="CR11">11</xref>]. BP and vascular function are regulated through the reversible nitric oxide-sensitive guanylate cyclase (NOsGC) pathway [<xref ref-type="bibr" rid="CR20">20</xref>]. The pathway that produces endothelial nitric oxide (eNOS) is the primary source of blood NO [<xref ref-type="bibr" rid="CR21">21</xref>]. eNOS knockout leads to hypertension and vascular dysfunction [<xref ref-type="bibr" rid="CR22">22</xref>]. Inadvertently, SIO exhibits radical scavenging activities against anionic, hydroxyl, ABTS and DPPH radicals that increase the pinocytosis of cells and increases NO production [<xref ref-type="bibr" rid="CR23">23</xref>]. We suggest that BP reduction via PUFA consumption yields additional clinical benefits, as the n-6:n-3 ratio in our SIO supplement was 1:1.25, which is considered to be an almost ideal ratio. A balance n-6:n-3 fatty acid ratio is crucial for reducing the risk of coronary heart disease [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec7"><title>Effects of SIO Versus Placebo Supplementation on Lipid Profiles</title><p id="Par11">Significant improvements in TC (-0.5&#x02009;&#x000b1;&#x02009;0.7 vs. 0.05&#x02009;&#x000b1;&#x02009;0.6 mmol/L; <italic>p</italic>&#x02009;=&#x02009;0.024), LDL-C (-0.3&#x02009;&#x000b1;&#x02009;0.7 vs. 0.2&#x02009;&#x000b1;&#x02009;0.6 mmol/L; <italic>p</italic>&#x02009;=&#x02009;0.036), and HDL-C (0.001&#x02009;&#x000b1;&#x02009;0.1 vs. -0.043&#x02009;&#x000b1;&#x02009;0.0 mmol/L; <italic>p</italic>&#x02009;=&#x02009;0.048) were observed in the SIO group after 12 weeks intervention (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The serum TG level remained unchange. Four months of consumption of 5 or 10 mL of SIO emulsion significantly reduced TC, LDL-C, non-HDL cholesterol, TG, VLDL and NEFAs in 24 hypercholesterolemic patients [<xref ref-type="bibr" rid="CR25">25</xref>]. An organoleptic study reported that SIO-supplemented high-fat diet attenuated the increase in TC, in addition to a reduction in interleukin-6 [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par12">ALA is known to modulate lipid metabolism, improve lipid homeostasis, increase fatty acid &#x003b2;-oxidation through the upregulation of peroxisome-activated receptor-&#x00251; and the downregulation of sterol regulatory element-binding protein-1 [<xref ref-type="bibr" rid="CR27">27</xref>]. Long chain omega-3 PUFAs, which are highly abundant in SIO, have potential health benefits for the modulation of balanced lipid profiles [<xref ref-type="bibr" rid="CR28">28</xref>]. Earlier literature found that SIO consumption mitigated the increase in lipopolysaccharide (LPS) entry into circulation, thus suppressing the correlation between LPS and TG through the inhibitory effect of PUFAs, even in the presence of high TG levels [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In addition, the effects of omega-3 PUFAs on lipolysis can be modulated by perilipin and/or hormone-sensitive lipase (HSL). Perilipin recovers intracellular lipidic particles in adipocytes, increases the access of HSL to adipocytes, and hydrolyses fatty droplets, leading to increased lipolysis. The lipoprotein lipase enzyme releases fatty acids through the hydrolysis of chylomicron and VLDL-triacylglycerol, reducing their level in the blood, thus resulting in a lipid-lowering effect [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par13">The current SIO supplement contributed approximately 88.8&#x000a0;mg of omega-9 fatty acid per day. Oleic acid is associated with cardiovascular insulin resistance, improved endothelial dysfunction in response to proinflammatory signals, and reduced proliferation and apoptosis in vascular smooth muscle cells (VSMCs) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. As such, we propose that oleic acid may partly involve in instability and underlying complications in the context of vascular smooth muscle remodelling. However, the detail pathway is yet to be fully understood.</p></sec><sec id="Sec8"><title>Compliance, Tolerability and Adherence</title><p id="Par14">All participants completed the trial. Most of the patients were well tolerated to the supplementation regimen. The main complaints were mild nausea (<italic>n</italic>&#x02009;=&#x02009;4) and mild gastrointestinal discomfort (<italic>n</italic>&#x02009;=&#x02009;2) during the first week of consumption. Adherence to the trial was 97% for the SIO group and 95% for the placebo group, respectively.</p><p id="Par15">The levels of ALA, linoleic acid (LA), oleic acid, total omega-3 PUFAs and total omega-6 PUFAs were significantly increased (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) after intervention with SIO (data not shown). In parallel, the plasma LA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and total omega-6 PUFAs were increased significantly (<italic>p</italic> &#x0003c; 0.05) in the placebo group.</p></sec></sec><sec id="Sec9"><title>Strengths and Limitations</title><p id="Par16">This was a preliminary trial to explore the role of SIO supplementation for the amelioration of hyperglycaemia, hypertension and hyperlipidaemia. Daily supplementation with 1000&#x000a0;mg of SIO for 12 weeks significantly improved BP and lipid profiles in patients with 3Hs. Both trial groups reported high supplement adherence throughout the study. As such, nutritional supplement interventions could be the primary strategies for ameliorating hypertension and hyperlipidaemia. Furthermore, each patient underwent direct screening and recruitment procedures. By enrolling patients with similar characteristics and conditions, the variability within the study population is minimised. Nonetheless, our study has several limitations. These limitations include the relatively small sample size, which commonly arises due to the use of stringent inclusion and exclusion criteria in the trial. We suggest that a longer study period may be recommended for future studies to assess more accurate intervention outcomes. Furthermore, it would be beneficial to measure the NO levels in 3Hs patients.</p></sec><sec id="Sec10"><title>Conclusion</title><p id="Par17">This preliminary study demonstrated encouraging results of SIO supplementation on BP and lipid profile management in individuals with 3Hs. SIO supplementation has the potential to alleviate BPs, while reducing TC and LDL-C and improving HDL-C. This trial may contribute to the dissemination of reliable findings that may support the recommendation of the novel SIO as complementary medicine. Future studies with larger sample sizes, longer intervention periods and modified SIO compositions should be planned before conclusive recommendations can be made.</p></sec><sec id="Sec11" sec-type="supplementary-material"><title>Electronic Supplementary Material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11130_2025_1309_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="11130_2025_1309_MOESM2_ESM.docx"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>Conceptualization: Mohd Sopian M, LK Lee; Investigation: Mhd Rodzi NAR, Mohd Sopian M and LK Lee; Writing&#x02013; original draft: Mhd Rodzi, NAR; Writing&#x02013; review and editing: Mohd Sopian M and LK Lee; Supervising: Mohd Sopian M and LK Lee.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The study was funded by Orient Biotech Sdn Bhd under the Double Tax Deduction Grant Scheme [Project code: 304/PTEKIND/6501176/O107].</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>Data cannot be shared openly to protect the patients&#x02019; privacy.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics Approval and Consent to Participate</title><p id="Par18">The trial was conducted according to the guidelines of the Declaration of Helsinki. The study was adhered to the CONSORT guidelines. Participation consent was obtained from all individuals, and they signed publication consent. The study was approved by the university human ethical committee (protocol certification number: USM/JEPeM/20120710). The study has also been registered with the National Medical Research Register (NMRR), with the registration number NMRR-20-3234-56756. The clinical trial has been registered in the clinical trial registry (ClinicalTrials.gov) (study registration date: First registration: 26th May 2021; First submitted that met QC criteria: 3rd June 2021; First posted: 10th June 2021), with the registration ID: NCT04920825.</p></notes><notes id="FPar2"><title>Consent for Publication</title><p id="Par19">All participants signed the consent for publication.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing Interests</title><p id="Par20">LK Lee received the SIO from Orient Biotech Sdn. Bhd. Mhd Rodzi NAR and Mohd Sopian M declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="book"><person-group person-group-type="author"><collab>Clinical Practice Guidelines</collab></person-group><source>Management of type 2 diabetes Mellitus, Sixth Edition</source><year>2020</year><publisher-loc>Putrajaya</publisher-loc><publisher-name>Ministry of Health, Malaysia</publisher-name></element-citation><mixed-citation id="mc-CR1" publication-type="book">Clinical Practice Guidelines (2020) Management of type 2 diabetes Mellitus, Sixth Edition. Ministry of Health, Malaysia., Putrajaya</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Clinical Practice Guidelines: Management of Hypertension 5th Edition (2018) Ministry of Health Malaysia. 160</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Shankar</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>GP</given-names></name></person-group><article-title>Prevalence and Associated Risk factors of hypertension: a cross-sectional study in Urban Varanasi</article-title><source>Int J Hypertens</source><year>2017</year><volume>2017</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2017/5491838</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Singh S, Shankar R, Singh GP (2017) Prevalence and Associated Risk factors of hypertension: a cross-sectional study in Urban Varanasi. Int J Hypertens 2017:1&#x02013;10. 10.1155/2017/5491838</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Farhat</surname><given-names>A</given-names></name><name><surname>Al-Hajje</surname><given-names>A</given-names></name><name><surname>Rachidi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Risk factors and quality of life of dyslipidemic patients in Lebanon: a cross-sectional study</article-title><source>J Epidemiol Global Health</source><year>2016</year><volume>6</volume><issue>4</issue><fpage>315</fpage><pub-id pub-id-type="doi">10.1016/j.jegh.2016.10.001</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Farhat A, Al-Hajje A, Rachidi S et al (2016) Risk factors and quality of life of dyslipidemic patients in Lebanon: a cross-sectional study. J Epidemiol Global Health 6(4):315. 10.1016/j.jegh.2016.10.001</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">5th Edition of Clinical Practice Guidelines: Management of Dyslipidaemia. (2017)</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Magliano D, Boyko EJ (2021) IDF diabetes atlas. 10th edition. Brussels: International Diabetes Federation; <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK581934/">https://www.ncbi.nlm.nih.gov/books/NBK581934/</ext-link></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">S&#x000e1;nchez EG, Hern&#x000e1;ndez-Ledesma B, Guti&#x000e9;rrez LF (2021) Sacha Inchi Oil Press-cake: physicochemical characteristics, Food-related applications and biological activity. Food Reviews Int 1&#x02013;12. 10.1080/87559129.2021.1900231</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Zhang</surname><given-names>HM</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><etal/></person-group><article-title>A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial</article-title><source>Lipids Health Dis</source><year>2019</year><volume>18</volume><issue>106</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12944-019-1048-x</pub-id><pub-id pub-id-type="pmid">30621696</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wang JF, Zhang HM, Li YY et al (2019) A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial. Lipids Health Dis 18(106):9. 10.1186/s12944-019-1048-x<pub-id pub-id-type="pmid">30621696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Ursoniu</surname><given-names>S</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name><name><surname>Andrica</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trial</article-title><source>Clin Nutr</source><year>2016</year><volume>35</volume><issue>3</issue><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2015.05.012</pub-id><pub-id pub-id-type="pmid">26071633</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ursoniu S, Sahebkar A, Andrica F et al (2016) Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trial. Clin Nutr 35(3):615&#x02013;625. 10.1016/j.clnu.2015.05.012<pub-id pub-id-type="pmid">26071633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Esherick J, Slater E, David J Current Practice Guidelines in Primary Care 2020</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Breda J, Wickramasinghe K, Peters DH et al (2019) One size does not fit all: implementation of interventions for non-communicable diseases. BMJ l6434. 10.1136/bmj.l6434</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Alay&#x000f3;n</surname><given-names>AN</given-names></name><name><surname>Ortega Avila</surname><given-names>JG</given-names></name><name><surname>Echeverri Jim&#x000e9;nez</surname><given-names>I</given-names></name></person-group><article-title>Carbohydrate metabolism and gene expression of sirtuin 1 in healthy subjects after Sacha Inchi oil supplementation: a randomized trial</article-title><source>Food Funct</source><year>2018</year><volume>9</volume><issue>3</issue><fpage>1570</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1039/c7fo01956d</pub-id><pub-id pub-id-type="pmid">29437170</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Alay&#x000f3;n AN, Ortega Avila JG, Echeverri Jim&#x000e9;nez I (2018) Carbohydrate metabolism and gene expression of sirtuin 1 in healthy subjects after Sacha Inchi oil supplementation: a randomized trial. Food Funct 9(3):1570&#x02013;1577. 10.1039/c7fo01956d<pub-id pub-id-type="pmid">29437170</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>GF</given-names></name><name><surname>Gonzales</surname><given-names>C</given-names></name></person-group><article-title>A randomized, double-blind placebo-controlled study on acceptability, safety and efficacy of oral administration of Sacha Inchi oil (Plukenetia Volubilis L.) in adult human subjects</article-title><source>Food Chem Toxicol</source><year>2014</year><volume>65</volume><fpage>168</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2013.12.039</pub-id><pub-id pub-id-type="pmid">24389453</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Gonzales GF, Gonzales C (2014) A randomized, double-blind placebo-controlled study on acceptability, safety and efficacy of oral administration of Sacha Inchi oil (Plukenetia Volubilis L.) in adult human subjects. Food Chem Toxicol 65:168&#x02013;176. 10.1016/j.fct.2013.12.039<pub-id pub-id-type="pmid">24389453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>GF</given-names></name><name><surname>Gonzales</surname><given-names>C</given-names></name><name><surname>Villegas</surname><given-names>L</given-names></name></person-group><article-title>Exposure of fatty acids after a single oral administration of Sacha Inchi (<italic>Plukenetia Volubilis</italic> L.) and sunflower oil in human adult subjects</article-title><source>Toxicol Mech Methods</source><year>2014</year><volume>24</volume><issue>1</issue><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.3109/15376516.2013.850566</pub-id><pub-id pub-id-type="pmid">24090048</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Gonzales GF, Gonzales C, Villegas L (2014) Exposure of fatty acids after a single oral administration of Sacha Inchi (<italic>Plukenetia Volubilis</italic> L.) and sunflower oil in human adult subjects. Toxicol Mech Methods 24(1):60&#x02013;69. 10.3109/15376516.2013.850566<pub-id pub-id-type="pmid">24090048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>P</given-names></name><etal/></person-group><article-title>A metabolite of nobiletin, 4&#x02032;-demethylnobiletin and atorvastatin synergistically inhibits human colon cancer cell growth by inducing G0/G1 cell cycle arrest and apoptosis</article-title><source>Food Funct</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1039/c7fo01155e</pub-id><pub-id pub-id-type="pmid">29063088</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Wu X, Song M, Qiu P et al (2018) A metabolite of nobiletin, 4&#x02032;-demethylnobiletin and atorvastatin synergistically inhibits human colon cancer cell growth by inducing G0/G1 cell cycle arrest and apoptosis. Food Funct 9(1):87&#x02013;95. 10.1039/c7fo01155e<pub-id pub-id-type="pmid">29063088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Gorriti</surname><given-names>A</given-names></name><name><surname>Arroyo</surname><given-names>J</given-names></name><name><surname>Quispe</surname><given-names>F</given-names></name><etal/></person-group><article-title>Plukenetia Volubilis L.) Y LINAZA (Linum usitatissimum L)</article-title><source>Rev Peru Med Exp Salud Publica</source><year>2010</year><volume>27</volume><issue>3</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1590/S1726-46342011000400009</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Gorriti A, Arroyo J, Quispe F et al (2010) (Plukenetia Volubilis L.) Y LINAZA (Linum usitatissimum L). Rev Peru Med Exp Salud Publica 27(3):9. 10.1590/S1726-46342011000400009</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>M</given-names></name><name><surname>Petocz</surname><given-names>P</given-names></name><name><surname>Caterson</surname><given-names>ID</given-names></name><etal/></person-group><article-title>Effects of zinc and &#x003b1;-linolenic acid supplementation on glycemia and lipidemia in women with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial</article-title><source>J Diab Res Clin Met</source><year>2013</year><volume>2</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="doi">10.7243/2050-0866-2-3</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Foster M, Petocz P, Caterson ID et al (2013) Effects of zinc and &#x003b1;-linolenic acid supplementation on glycemia and lipidemia in women with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. J Diab Res Clin Met 2(1):3. 10.7243/2050-0866-2-3</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zuo</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of n-3 polyunsaturated fatty acid on metabolic status in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials</article-title><source>J Ovarian Res</source><year>2023</year><volume>16</volume><issue>1</issue><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s13048-023-01130-4</pub-id><pub-id pub-id-type="pmid">36932420</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zhou J, Zuo W, Tan Y et al (2023) Effects of n-3 polyunsaturated fatty acid on metabolic status in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. J Ovarian Res 16(1):54. 10.1186/s13048-023-01130-4<pub-id pub-id-type="pmid">36932420</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Savini</surname><given-names>I</given-names></name><name><surname>Catani</surname><given-names>M</given-names></name><name><surname>Evangelista</surname><given-names>D</given-names></name><etal/></person-group><article-title>Obesity-Associated oxidative stress: strategies finalized to Improve Redox State</article-title><source>IJMS</source><year>2013</year><volume>14</volume><issue>5</issue><fpage>10497</fpage><lpage>10538</lpage><pub-id pub-id-type="doi">10.3390/ijms140510497</pub-id><pub-id pub-id-type="pmid">23698776</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Savini I, Catani M, Evangelista D et al (2013) Obesity-Associated oxidative stress: strategies finalized to Improve Redox State. IJMS 14(5):10497&#x02013;10538. 10.3390/ijms140510497<pub-id pub-id-type="pmid">23698776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Signalling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions</article-title><source>Sig Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>168</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01430-7</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ma J, Li Y, Yang X et al (2023) Signalling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther 8(1):168. 10.1038/s41392-023-01430-7</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Youn</surname><given-names>JY</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension</article-title><source>J Hypertens</source><year>2015</year><volume>33</volume><issue>6</issue><fpage>1128</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000000587</pub-id><pub-id pub-id-type="pmid">25882860</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Li Q, Youn JY, Cai H (2015) Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J Hypertens 33(6):1128&#x02013;1136. 10.1097/HJH.0000000000000587<pub-id pub-id-type="pmid">25882860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>G</given-names></name><name><surname>Volpe</surname><given-names>M</given-names></name><name><surname>Savoia</surname><given-names>C</given-names></name></person-group><article-title>Endothelial dysfunction in hypertension: current concepts and clinical implications</article-title><source>Front Med</source><year>2022</year><volume>8</volume><fpage>798958</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.798958</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Gallo G, Volpe M, Savoia C (2022) Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med 8:798958. 10.3389/fmed.2021.798958</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sacha Inchi oil alleviates gut microbiota dysbiosis and improves hepatic lipid dysmetabolism in high-fat diet-fed rats</article-title><source>Food Funct</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1039/d0fo01178a</pub-id><pub-id pub-id-type="pmid">29063088</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Li P, Huang J, Xiao N et al (2018) Sacha Inchi oil alleviates gut microbiota dysbiosis and improves hepatic lipid dysmetabolism in high-fat diet-fed rats. Food Funct 9(1):87&#x02013;95. 10.1039/d0fo01178a<pub-id pub-id-type="pmid">29063088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Desai</surname><given-names>SS</given-names></name><name><surname>Mane</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Futuristic food fortification with a balanced ratio of dietary &#x003c9;-3/&#x003c9;-6 omega fatty acids for the prevention of lifestyle diseases</article-title><source>Trends Food Sci Technol</source><year>2022</year><volume>120</volume><fpage>140</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.tifs.2022.01.006</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Patel A, Desai SS, Mane VK et al (2022) Futuristic food fortification with a balanced ratio of dietary &#x003c9;-3/&#x003c9;-6 omega fatty acids for the prevention of lifestyle diseases. Trends Food Sci Technol 120:140&#x02013;153. 10.1016/j.tifs.2022.01.006</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Garmendia F, Pando R, Ronceros G (2014) Efecto Del aceite de sacha inchi (Plukenetia vol&#x000fa;bilis L) Sobre El Perfil lip&#x000ed;dico en pacientes con hiperlipoproteinemia. Rev Peru Med Exp Salud Publica 28(4). 10.1590/S1726-46342011000400009</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Alay&#x000f3;n</surname><given-names>AN</given-names></name><name><surname>Ortega</surname><given-names>JG</given-names></name><name><surname>Echeverri</surname><given-names>JI</given-names></name></person-group><article-title>Metabolic status is related to the effects of adding of Sacha Inchi (<italic>Plukenetia Volubilis L</italic>.) oil on postprandial inflammation and lipid profile: Randomized, crossover clinical trial</article-title><source>J Food Biochem</source><year>2019</year><volume>43</volume><issue>2</issue><fpage>e12703</fpage><pub-id pub-id-type="doi">10.1111/jfbc.12703</pub-id><pub-id pub-id-type="pmid">31353666</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Alay&#x000f3;n AN, Ortega JG, Echeverri JI (2019) Metabolic status is related to the effects of adding of Sacha Inchi (<italic>Plukenetia Volubilis L</italic>.) oil on postprandial inflammation and lipid profile: Randomized, crossover clinical trial. J Food Biochem 43(2):e12703. 10.1111/jfbc.12703<pub-id pub-id-type="pmid">31353666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh-Ghadimi</surname><given-names>S</given-names></name><name><surname>Kheirouri</surname><given-names>S</given-names></name><name><surname>Golmohammadi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of flaxseed oil supplementation on anthropometric and metabolic indices in patients with coronary artery disease: a double-blinded randomized controlled trial</article-title><source>J Cardiovasc Thorac Res</source><year>2019</year><volume>11</volume><issue>2</issue><fpage>152</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.15171/jcvtr.2019.26</pub-id><pub-id pub-id-type="pmid">31384411</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Saleh-Ghadimi S, Kheirouri S, Golmohammadi A et al (2019) Effect of flaxseed oil supplementation on anthropometric and metabolic indices in patients with coronary artery disease: a double-blinded randomized controlled trial. J Cardiovasc Thorac Res 11(2):152&#x02013;160. 10.15171/jcvtr.2019.26<pub-id pub-id-type="pmid">31384411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name></person-group><article-title>Natural products and obesity: a focus on the regulation of mitotic clonal expansion during Adipogenesis</article-title><source>Molecules</source><year>2019</year><volume>24</volume><issue>6</issue><fpage>1157</fpage><pub-id pub-id-type="doi">10.3390/molecules24061157</pub-id><pub-id pub-id-type="pmid">30909556</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Chang E, Kim C (2019) Natural products and obesity: a focus on the regulation of mitotic clonal expansion during Adipogenesis. Molecules 24(6):1157. 10.3390/molecules24061157<pub-id pub-id-type="pmid">30909556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Lyte</surname><given-names>JM</given-names></name><name><surname>Gabler</surname><given-names>NK</given-names></name><name><surname>Hollis</surname><given-names>JH</given-names></name></person-group><article-title>Postprandial serum endotoxin in healthy humans is modulated by dietary fat in a randomized, controlled, cross-over study</article-title><source>Lipids Health Dis</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>186</fpage><pub-id pub-id-type="doi">10.1186/s12944-016-0357-6</pub-id><pub-id pub-id-type="pmid">27816052</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Lyte JM, Gabler NK, Hollis JH (2016) Postprandial serum endotoxin in healthy humans is modulated by dietary fat in a randomized, controlled, cross-over study. Lipids Health Dis 15(1):186. 10.1186/s12944-016-0357-6<pub-id pub-id-type="pmid">27816052</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Kell</surname><given-names>DB</given-names></name><name><surname>Pretorius</surname><given-names>E</given-names></name></person-group><article-title>On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death</article-title><source>Integr Biology</source><year>2015</year><volume>7</volume><issue>11</issue><fpage>1339</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1039/c5ib00158g</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kell DB, Pretorius E (2015) On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr Biology 7(11):1339&#x02013;1377. 10.1039/c5ib00158g</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Shetty SS, Kumari NS, Shetty PK (2020) &#x003c9;-6/&#x003c9;-3 fatty acid ratio as an essential predictive biomarker in the management of type 2 diabetes mellitus. Nutrition 79&#x02013;80. 10.1016/j.nut.2020.110968</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Perdomo</surname><given-names>L</given-names></name><name><surname>Beneit</surname><given-names>N</given-names></name><name><surname>Otero</surname><given-names>YF</given-names></name><etal/></person-group><article-title>Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><issue>1</issue><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0237-9</pub-id><pub-id pub-id-type="pmid">26055507</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Perdomo L, Beneit N, Otero YF et al (2015) Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process. Cardiovasc Diabetol 14(1):75. 10.1186/s12933-015-0237-9<pub-id pub-id-type="pmid">26055507</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>